Fatemeh Salabi | Biotechnology | Best Research Article Award

Published on by Invention Awards

Best Research Article Award

Fatemeh Salabi
Education and Extension Organization

Fatemeh Salabi
Affiliation Education and Extension Organization
Country Iran
Scopus ID 36161376900
Documents 30
Citations 174
h-index 9
Subject Area Biotechnology
Event International Invention Awards
ORCID 0000-0002-1753-5162

Fatemeh Salab is a biotechnology researcher affiliated with the Education and Extension Organization in Iran. Her documented research profile includes 30 Scopus-indexed documents, 174 citations, and an h-index of 9. These bibliometric indicators provide a quantitative context for considering her research activity and suitability for recognition through the Best Research Article Award.[1]

Abstract

Fatemeh Salab is a biotechnology researcher affiliated with the Education and Extension Organization in Iran, with a documented scholarly profile represented in Scopus and ORCID. The available bibliometric record identifies 30 documents, 174 citations, and an h-index of 9, providing measurable evidence of sustained research activity and scholarly visibility. Her subject-area classification in biotechnology places her work within a field that connects biological knowledge with applied scientific development and innovation. This article summarizes her research profile, publication record, measurable research impact, and relevance to the Best Research Article Award, while maintaining a neutral academic perspective based on the supplied researcher and bibliometric information.[1][2]

Keywords

Fatemeh Salab; Best Research Article Award; biotechnology; scientific research; research publications; bibliometric impact; Scopus; ORCID; scholarly communication; research innovation; biotechnology research; Iran.

Introduction

Biotechnology encompasses research that applies biological systems, organisms, cells, and molecular processes to scientific and practical challenges. Scholarly evaluation in this field commonly considers publication activity, citation performance, research continuity, and the relevance of contributions to the broader scientific community. Bibliometric databases such as Scopus provide structured indicators that can assist in contextualizing an individual research profile.[1]

Research Profile

Fatemeh Salab’s supplied research profile identifies the Education and Extension Organization as her institutional affiliation and biotechnology as her principal subject area. The reported Scopus record contains 30 documents, 174 citations, and an h-index of 9. Her ORCID identifier provides an additional persistent researcher identifier for distinguishing her scholarly record across research information systems.[1][2]

Research Contributions

The available information supports describing Salab’s research contributions within the broader biotechnology domain rather than assigning specific findings without individual publication evidence. Her documented publication volume indicates sustained scholarly participation, while the citation record suggests that published work has received measurable attention within indexed academic literature. Detailed assessment of individual contributions should consider the content and methodological quality of each article.[1]

Publications

The supplied bibliometric information reports 30 documents associated with Scopus Author ID 36161376900. This publication count establishes a documented body of indexed scholarly output, although the available input does not provide individual article titles, journals, publication years, authorship positions, or Digital Object Identifiers. Consequently, publication-level conclusions are appropriately limited to the documented bibliometric information.[1]

Research Impact

The reported 174 citations and h-index of 9 provide quantitative indicators of scholarly visibility for the documented research record. Citation metrics should be interpreted in relation to disciplinary norms, publication age, collaboration patterns, and research field characteristics rather than as standalone measures of scientific quality. Nevertheless, these indicators provide useful context when reviewing the profile for academic recognition.[1]

Award Suitability

The Best Research Article Award is appropriately considered in relation to the quality, originality, methodological rigor, relevance, and scholarly contribution of the nominated article. Salab’s documented biotechnology research profile, publication activity, citation record, and persistent researcher identification provide contextual evidence for consideration. Final award assessment should remain dependent on the nominated article and the applicable evaluation criteria of the event.[1][4]

Conclusion

Fatemeh Salab has a documented biotechnology research profile associated with the Education and Extension Organization in Iran. The supplied record indicates 30 Scopus documents, 174 citations, and an h-index of 9, alongside an ORCID identifier supporting researcher identification.[1][2] These indicators establish a useful scholarly profile for consideration under the Best Research Article Award, while article-level evaluation remains essential for determining research quality and distinction.

References

  1. Elsevier. (n.d.). Scopus author details: Fatemeh Salab, Author ID 36161376900. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=36161376900
  2. ORCID. (n.d.). ORCID record: Fatemeh Salab. ORCID.
    https://orcid.org/0000-0002-1753-5162
  3. Research article (2026. ) Modulation of ERs/Nrf2–Keap1 Signaling Pathway by Ethinylestradiol in Juvenile Common Carp (Cyprinus carpio): Implications for Oxidative Stress and Estrogenic Effects.
    https://doi.org/10.1002/clen.70255
  4. International Invention Awards. (2026. ). Award website
    https://inventionawards.org/
  5. Research article (2025. ) A computational study of venom as drug library: Discovery of multifunctional astacin-like metalloproteases from Androctonus zagrosensis venom gland transcriptome.
    https://doi.org/10.23640/07243.11555

Serena Travaglini | Genetics and Molecular Biology | Best Researcher Award

Published on by Invention Awards

Dr. Serena Travaglini | Genetics and Molecular Biology | Best Researcher Award

Dr. Serena Travaglini | University of Rome Tor Vergata  | Italy

Dr. Serena Travaglini is a dedicated molecular biologist and researcher at the University of Rome “Tor Vergata” specializing in the characterization of leukemia stem cells. Born in Rome, she advanced through a strong academic trajectory in biotechnology, earning bachelor’s, master’s, and doctoral degrees from Tor Vergata University. She conducted her doctoral research under leading mentors, focusing on FLT3-ITD-mutated acute myeloid leukemia, identifying novel therapeutic targets. After completing her doctorate, she deepened her expertise in postdoctoral studies exploring CD99 as a therapeutic marker and the transcriptomic evolution of AML. Currently, she leads investigations into the role of p63 in thymoma within the Laboratory of Biochemistry and Molecular Biology. With a solid foundation in molecular biotechnology and translational medicine, Dr. Travaglini exemplifies excellence in both research innovation and academic leadership.

Profiles

Scopus
Orcid

Education and Experience

Dr. Travaglini’s academic journey reflects sustained dedication to biotechnology and translational medicine. She graduated in biotechnology and advanced to earn a master’s in medical biotechnology, followed by a PhD in biotechnology and translational medicine, all at Tor Vergata University. Her early research explored oxidative stress in neurodegenerative diseases and the molecular interplay in APL. During her doctoral studies, she investigated FLT3-ITD-mutated leukemia stem cells, pursuing actionable targets to impede relapse. Her postdoctoral work further expanded her expertise by analyzing CD99’s role in leukemic progenitor cell behavior and homing. As a researcher, she now explores p63’s involvement in thymoma, integrating molecular insights with translational goals. Her progression reflects a consistent focus on dissecting leukemic pathophysiology to inform therapeutic strategies.

Research Interests

Dr. Travaglini’s research spans the genetic and cellular characterization of leukemia, with a distinctive focus on leukemia stem cells and clonal evolution. She is deeply interested in validating genetic biomarkers in AML and APL, exploring therapeutic vulnerabilities, and understanding resistance in arsenic-trioxide-treated APL. Her work includes analysis of surface immunophenotypes including CD99, CD34, and CD123, and characterizing t(11;17)-positive AMLs. She also investigates therapy-related AML and how genetic changes drive disease progression. Her broader goals emphasize leveraging multiparameter flow cytometry, genetics, and in vivo modeling to inform precision medicine strategies that combat recurrence and treatment resistance.

Awards & Recognition

Dr. Travaglini is the recipient of notable recognitions for her contributions to life sciences research. She received the Angeletti-Mortari Life Sciences Research Prize from MSD Italia—an award honoring innovation by emerging researchers and supporting their work in scientific excellence within Italy. She also won the “AIL Beat Leukemia” Fellowship awarded by the Italian Society of Experimental Hematology, which advanced her project investigating the molecular landscape of high-risk acute promyelocytic leukemia and strategies to overcome disease progression beat-leukemia.org. These honors reflect her impactful contributions to leukemia research and her promise as a leading young scientist.

Publications Top Notes

Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non‐canonical FLT3 mutation: A proof of concept

Journal: British Journal of Haematology
Authors: Serena Travaglini, Carmelo Gurnari, Silvia Antonelli, Francesco Marchesi, Gioia De Angelis, Tiziana Ottone, Mariadomenica Divona, Antonio Cristiano, Hajro Hajrullaj, Andrea Mengarelli, et al.

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Journal:  Cancers 
Authors: Cristina Banella, Gianfranco Catalano, Serena Travaglini, Elvira Pelosi, Tiziana Ottone, Alessandra Zaza, Gisella Guerrera, Daniela Francesca Angelini, Pasquale Niscola, Mariadomenica Divona, et al.

From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression

Journal: Biology 
Authors: Carmelo Gurnari, Emiliano Fabiani, Giulia Falconi, Serena Travaglini, Tiziana Ottone, Antonio Cristiano, Maria Teresa Voso.

PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells

Journal: Cancers 
Authors: Cristina Banella, Gianfranco Catalano, Serena Travaglini, Mariadomenica Divona, Silvia Masciarelli, Gisella Guerrera, Francesco Fazi, Francesco Lo-Coco, Maria Teresa Voso, Nelida Ines Noguera.

Conclusion

Dr. Serena Travaglini stands as a distinguished emerging researcher in molecular hematology, demonstrating both scientific rigor and translational vision. Her academic excellence, from her foundational training through her innovative postdoctoral and current work, underscores her commitment to unraveling the biological mechanisms underpinning leukemia and resistance. Her strategically focused research on leukemia stem cells, therapeutic biomarker validation, and overcoming drug-resistant APL speaks to her potential to influence next-generation leukemia therapies. Recognition through prestigious awards and notable scholarly contributions further affirm her candidacy. With continued support, Dr. Travaglini is poised to lead impactful research initiatives that can reshape treatment paradigms in acute leukemia and precision medicine.